Recent Updates
Recently added Catalysts

Metastatic Lung Cancer: one US-listed biotech with a clinical-stage programme

OncologyUncontestedData as of 2026-09-04

Competitors1in the clinic
Median market cap$486Muniverse median $1.20B
Allocated capital$162M$486M competing
Phase 3 or filed00 mid, 1 early
Pure plays0this indication only
Capital rank265/299crowding rank 267

Metastatic Lung Cancer is uncontested. Puma Biotechnology (PBYI) is the only US-listed developer in the $100M to $20B band running a clinical programme here, with Alisertib in phase 1.

There is no public comparable to price it against. PBYI spreads its $486M market cap across 3 indications, so $162M of it is allocated here.

Nothing here has reached Phase 3: 0 programmes in mid stage and 1 in early stage, so the field is still several years from a first approval.

$162M of allocated capital sits in Metastatic Lung Cancer, ranking it 265th of 299 indications by the money committed to it.

Companies developing drugs for Metastatic Lung Cancer 1

TickerCompanyLead assetPhaseTrialsMarket capPure playIndicationsNext catalyst
PBYIPuma BiotechnologyAlisertibPhase 11$486MNo3No dated event

Sorted by phase, then by market capitalisation. Ticker links open the company profile.

Why Metastatic Lung Cancer counts as uncontested

Uncontested. One US-listed developer in the size band is running a clinical programme here, so there is no public comparable to price it against.

The map splits indications on two folds: six or more competitors counts as crowded, and a median company above $1.20B counts as richly priced. Metastatic Lung Cancer has one competitor and a median of $486M.

Oncology

Oncology holds $187B of the map's capital, 27.8% of the total, spread across 119 indications and 103 companies. 34 of those indications have more than one company competing.

See every Oncology indication on the map

Related indications in Oncology

Relapsed and Refractory Multiple Myeloma1 company · $156M · median $156MUncontestedAdvanced Hepatocellular Carcinoma1 company · $175M · median $175MUncontestedT-Cell Lymphoblastic Leukemia/Lymphoma2 companies · $149M · median $374MOrphan cornerLeukemia1 company · $176M · median $176MUncontestedChronic Myeloid Leukemia1 company · $180M · median $1.6BUncontestedPhiladelphia Chromosome Positive Acute Lymphocytic Leukemia1 company · $180M · median $1.6BUncontestedLiposarcoma1 company · $180M · median $1.6BUncontestedStage IV Merkel Cell Carcinoma1 company · $134M · median $134MUncontested

Metastatic Lung Cancer pipeline questions

Which biotech companies are developing drugs for Metastatic Lung Cancer?

Puma Biotechnology (PBYI, Alisertib, Phase 1). Those are the 1 US-listed developer in the $100M to $20B market cap band with a clinical-stage programme in Metastatic Lung Cancer.

How advanced is the Metastatic Lung Cancer pipeline?

Of the 1 clinical-stage programme in Metastatic Lung Cancer, 0 are in Phase 3 or filed, 0 are in mid-stage development and 1 is in early-stage development.

Is anyone else developing a drug for Metastatic Lung Cancer?

No. PBYI is the only US-listed company in the $100M to $20B market cap band with a clinical-stage programme in Metastatic Lung Cancer, which is why the indication is classified as uncontested.

How this page is built

  • Universe is US-listed drug developers with a $100M to $20B market capitalisation, identified by SEC SIC code 2833, 2834 or 2836 or by a pharmaceutical or biotechnology industry classification, less a reviewed exclusion list of contract research organisations, device and diagnostics makers and diversified generics manufacturers.
  • An asset attributed to three or more different companies is treated as shared standard of care rather than any one company’s programme and excluded. Pembrolizumab alone appears under 21 tickers in raw trial data.
  • A programme counts only where at least one industry-sponsored trial supports it, so investigator-initiated academic studies of third-party drugs are excluded.

Allocated capital divides each company’s market capitalisation evenly across the indications it is running clinical programmes in, so every dollar of the universe is counted exactly once. Total market capitalisation competing counts a company in each of its indications and therefore sums to more than the universe.

Third-party market size estimates are not used anywhere on this page. Approved incumbents are excluded from competitor counts, and companies above $20B are outside the universe by construction.

Back to the disease map